- Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
-
Kim KI
- KMID: 2414912
- Korean Circ J.
- 2018 May;48(5):430-432.
- doi: 10.4070/kcj.2018.0085
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)
-
Koh G
- KMID: 2410878
- J Obes Metab Syndr.
- 2018 Mar;27(1):71-72.
- doi: 10.7570/jomes.2018.27.1.71
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Novel Therapies for Type 2 Diabetes Mellitus
-
Ko JM
- KMID: 1819674
- J Korean Soc Pediatr Endocrinol.
- 2009 Jun;14(1):11-18.
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and betacell dysfunction. The role of new hormones and systems in maintaining blood glucose... -
- CITED
-
- Close
- SHARE
-
- Close
- Response: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)
-
Lee JY, Jang BK, Song MK, Kim HS, Kim MK
- KMID: 2410879
- J Obes Metab Syndr.
- 2018 Mar;27(1):73-74.
- doi: 10.7570/jomes.2018.27.1.73
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
-
Lim SW, Jin JZ, Jin L, Jin J, Li C
- KMID: 2381580
- Korean J Intern Med.
- 2015 Nov;30(6):759-770.
- doi: 10.3904/kjim.2015.30.6.759
Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and... -
- CITED
-
- Close
- SHARE
-
- Close
- Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
-
Broxmeyer
- KMID: 1780121
- Korean J Intern Med.
- 2013 Nov;28(6):639-645.
- doi: 10.3904/kjim.2013.28.6.639
Dipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a... -
- CITED
-
- Close
- SHARE
-
- Close
- Increased Plasma Dipeptidyl Peptidase IV Activities in ob/ob Mice
-
Rhee SD, Lee YS, Lee HS, Jung WH, Cheon HG, Ahn JH, Kim SS, Paik SG, Yang SD
- KMID: 2177801
- J Korean Diabetes Assoc.
- 2005 Jan;29(1):22-29.
BACKGROUND: Dipeptidyl peptidase IV (DPP IV/CD26), a multi-functional glycoprotein, cleaves and inactivates major insulinotropic hormones, such as glucagon-like protein (GLP)-1 and glucose dependent insulinotrophic polypeptide (GIP). METHODS: The plasma DPP... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
-
Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH
- KMID: 2470293
- J Obes Metab Syndr.
- 2019 Dec;28(4):254-261.
- doi: 10.7570/jomes.2019.28.4.254
BACKGROUND: Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We analyzed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
-
Son JW, Kim S
- KMID: 2174010
- Diabetes Metab J.
- 2015 Oct;39(5):373-383.
- doi: 10.4093/dmj.2015.39.5.373
Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability.... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Influencing Glycemic Control Response of Sitagliptin
-
Kim GW, Kim JH, Lee MY, Shin JY, Shin YG, Ha EH, Chung CH
- KMID: 2173938
- J Korean Diabetes.
- 2013 Dec;14(4):206-211.
- doi: 10.4093/jkd.2013.14.4.206
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to reduce blood glucose in type 2 diabetes by prolonging the activity of circulating incretins. However, the factors that affect the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus
-
Cho EH, Kim SW
- KMID: 2460976
- Diabetes Metab J.
- 2019 Feb;43(1):97-104.
- doi: 10.4093/dmj.2018.0030
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) is strongly expressed in the kidney, and soluble levels of this protein are used as a marker in various chronic inflammatory diseases, including diabetes, coronary artery... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
-
Chang JS, Shin J, Kim HS, Kim KH, Shin JA, Yoon KH, Cha BY, Son HY, Cho JH
- KMID: 2280745
- Diabetes Metab J.
- 2013 Feb;37(1):72-80.
- doi: 10.4093/dmj.2013.37.1.72
BACKGROUND: The aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes. METHODS: In this retrospective study, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
-
Kim NH, Kim DL, Kim KJ, Kim NH, Choi KM, Baik SH, Kim SG
- KMID: 2384083
- Endocrinol Metab.
- 2017 Jun;32(2):241-247.
- doi: 10.3803/EnM.2017.32.2.241
BACKGROUND: Glycemic variability is associated with the development of diabetic complications through the activation of oxidative stress. This study aimed to evaluate the effects of a dipeptidyl peptidase 4 inhibitor,... -
- CITED
-
- Close
- SHARE
-
- Close
- High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women
-
Kim SW, Cho EH
- KMID: 2169698
- Endocrinol Metab.
- 2016 Mar;31(1):93-99.
- doi: 10.3803/EnM.2016.31.1.93
BACKGROUND: Dipeptidyl peptidase 4/CD26 (DPP-4) is a widely expressed cell surface serine protease. DPP-4 inhibitors, one of common anti-diabetic agents play a protective role in bone metabolism in recent studies.... -
- CITED
-
- Close
- SHARE
-
- Close
- Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus
-
Ko SH
- KMID: 2458963
- J Korean Diabetes.
- 2019 Sep;20(3):142-148.
- doi: 10.4093/jkd.2019.20.3.142
For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated.... -
- CITED
-
- Close
- SHARE
-
- Close
- Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
-
Kim SW
- KMID: 2222359
- Korean Diabetes J.
- 2010 Dec;34(6):331-337.
- doi: 10.4093/kdj.2010.34.6.331
Although there is no HbA1c threshold for cardiovascular risk, the American Diabetic Association-recommended goal of HbA1c < 7.0% appears to be unacceptably high. To achieve an optimal HbA1c level goal... -
- CITED
-
- Close
- SHARE
-
- Close
- Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity
-
Lee JG, Kang DG, Yu JR, Kim YR, Kim JS, Koh GP, Lee DH
- KMID: 2281713
- Diabetes Metab J.
- 2011 Apr;35(2):149-158.
- doi: 10.4093/dmj.2011.35.2.149
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with... -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics of Hypoglycemia Pateints Visiting the Emergency Department of a University Hospital
-
Choi SH, Youn DK, Choi MG, Ryu OH
- KMID: 2354286
- J Korean Diabetes.
- 2016 Sep;17(3):202-211.
- doi: 10.4093/jkd.2016.17.3.202
BACKGROUND: Hypoglycemia is an important obstacle in the treatment of diabetes. When diabetic patients experience hypoglycemia, thorough glycemic control is more difficult. We evaluated the factors associated with risk of... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of Autoimmune Diabetes by Inhibiting the Initial Event
-
Lee MS
- KMID: 1493613
- Immune Netw.
- 2013 Oct;13(5):194-198.
- doi: 10.4110/in.2013.13.5.194
Recent papers have shown that the initial event in the pathogenesis of autoimmune type 1 diabetes (T1D) comprises sensing of molecular patterns released from apoptotic beta-cells by innate immune receptors... -
- CITED
-
- Close
- SHARE
-
- Close
- Sodium butyrate has context-dependent actions on dipeptidyl peptidase-4 and other metabolic parameters
-
Lee ES, Lee DS, Pandeya PR, Kim YC, Kang DG, Lee HS, Oh BC, Lee DH
- KMID: 2388697
- Korean J Physiol Pharmacol.
- 2017 Sep;21(5):519-529.
- doi: 10.4196/kjpp.2017.21.5.519
Sodium butyrate (SB) has various metabolic actions. However, its effect on dipeptidyl peptidase 4 (DPP-4) needs to be studied further. We aimed to evaluate the metabolic actions of SB, considering... -
- CITED
-
- Close
- SHARE
-
- Close
